🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Industrials Sector SEC Filings — July 23, 2026

The S&P 500 Industrials sector delivered a robust Q2 2026, with top-line growth across aerospace, defense, and rail, but margin pressures from surging fuel costs and mixed operating leverage are key cross-cutting themes. Revenue growth was strong and broad-based: RTX (+14.5%), Lockheed Martin (+11%), Union Pacific (+12%), Norfolk Southern (+11.4%), and Honeywell (+4%) all reported solid gains, driven by defense demand, aftermarket services, and fuel surcharge pass-throughs. However, profitability was under siege: fuel expenses surged 60%+ YoY for both Union Pacific and Norfolk Southern, causing operating ratio deterioration and margin compression. The defense sector showed a dramatic earnings recovery, with Lockheed Martin's net income surging 5x YoY as prior-year program losses did not repeat, while RTX posted a 29% net income gain. Capital allocation diverged sharply: Lockheed Martin eliminated buybacks entirely, while Otis accelerated repurchases to $807M in H1. Insider activity was limited but notable, with two 3M executives selling shares post-exercise. Forward-looking guidance was positive, with RTX and Lockheed Martin raising full-year outlooks, while Honeywell provided a mixed picture with raised organic growth but lowered sales guidance. The key portfolio-level insight is a sector bifurcating into high-growth defense primes with strong cash flows and transportation companies facing cost headwinds that may persist if fuel prices remain elevated.

9 high priority 5 medium 14 total filings
· daily

US Material Events SEC 8-K Filings — July 23, 2026

The July 23, 2026, filing batch reveals a market dominated by capital market events (SPAC IPOs, debt financings, and at-the-market offerings) and significant corporate actions (M&A, divestitures, and leadership transitions). Key period-over-period trends show a mixed earnings picture in the industrial and auto-tech sectors, with Gentherm and Visteon reporting divergent results: Gentherm posted record revenue (+11% YoY) but suffered a sharp cash flow decline, while Visteon saw a 31% drop in net income. A clear sector theme is the aggressive restructuring and refocusing of smaller-cap companies, with several firms divesting non-core assets (LightPath, Tharimmune) or expanding via acquisition (HF Foods, Vireo Growth) to improve financial profiles and growth trajectories. Insider activity was limited to compensation-driven equity grants, providing no clear conviction signals, but forward-looking guidance changes (Gentherm raising full-year revenue outlook) and a flurry of new financing facilities (ADTRAN, Virtu Financial) point to a strategic push for liquidity and growth capital. The most critical developments include the Vireo Growth acquisition of distressed Cannabist assets, the HF Foods cross-border expansion, and the significant CFO transitions at GE HealthCare and Coastal Financial, all of which carry material implications for their respective sectors.

50 high priority 50 total filings
· daily

Insider Trading Pulse — July 23, 2026

Today's insider trading digest reveals a market dominated by routine compensation-related transactions (awards, option exercises, tax withholdings) masking pockets of significant conviction and concern. The most actionable signals cluster around three themes: aggressive insider buying in small-cap value plays (Byrna Technologies, Rani Therapeutics), large-scale insider selling at mega-cap insurers (Travelers) and a biotech (MoonLake), and a notable cluster of director option awards at Perma-Fix Environmental Services. Period-over-period comparisons are limited as most filings lack revenue/earnings data, but the insider activity itself provides powerful signals. The CEO of Byrna Technologies bought $65K worth of stock at $3.46, while the CFO of Travelers sold $4.06M at $368, representing a stark divergence in management conviction. The 51Talk CEO's $3.08M open-market purchase under a 10b5-1 plan is the largest insider buy by value and signals strong confidence in the company's turnaround. The Perma-Fix director awards (7 directors each receiving 10,000 options) suggest a board-level alignment strategy ahead of potential catalysts. Overall, the digest points to a bifurcated market where insiders at smaller, under-followed companies are putting capital to work while executives at larger, richly-valued names are taking profits.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — July 23, 2026

This digest of 15 Dow 30 filings reveals a period of significant corporate restructuring and capital deployment, with mixed operational performance beneath headline growth. Alphabet's reported net income surge is largely a non-operational anomaly from other income, while its debt and asset base have expanded dramatically, signaling aggressive M&A and investment. Honeywell is executing a major portfolio transformation, completing its Aerospace spin-off and raising guidance for its remaining 'Technologies' segment, yet its cash flow from operations has halved. Insider selling is a dominant theme, with three Travelers executives and two 3M executives collectively cashing out over $11 million in stock, a bearish signal for the insurance and industrial sectors. JPMorgan's $9 billion debt issuance indicates a strategic move to lock in funding, while Johnson & Johnson shows steady top-line growth but flat earnings, with rising SG&A costs. The overall picture is one of companies actively reshaping their portfolios (Honeywell, Alphabet) and executives reducing exposure (Travelers, 3M), against a backdrop of mixed fundamental trends.

12 high priority 3 medium 15 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 23, 2026

This intelligence digest covers five SEC 8-K filings from July 23, 2026, all involving Nasdaq compliance issues and acute corporate distress. The filings are dominated by three distinct distress signals: two companies (Nuvve, Fly-E Group) are delinquent on periodic reports (10-Q/10-K), three (Nuvve, Aprea Therapeutics, InspireMD) fail the $1.00 minimum bid price rule, and one (Shore Bancshares) faces audit committee independence violations. The most severe case is Nuvve Holding Corp., which faces an immediate trading suspension and transition to the OTC Pink market due to compounding non-compliance with three separate listing rules, signaling a high probability of equity value destruction. Across the group, no company reported revenue growth or positive forward guidance; the distress is wholly structural and regulatory. The presence of multiple delisting notices in a single day underscores a tightening enforcement environment by Nasdaq, potentially signaling broader market stress that may push more micro-cap issuers into non-compliance. The only partial reprieve is Fly-E Group, which filed its overdue 10-K on the same day as its notice, likely curing the deficiency. Investors should treat nearly all these companies as high-risk, with Nuvve being a near-certain loss of exchange listing and likely total equity impairment.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — July 23, 2026

The 42 filings from July 23, 2026, reveal a high-stakes environment dominated by insolvencies, delistings, and strategic M&A. Key themes include a wave of Nasdaq delisting risks (5 companies), active insolvency proceedings (3 companies with NCLT involvement), and a flurry of M&A activity in India, particularly in the mid-cap and specialty sectors. Period-over-period data shows mixed financial health: Gentherm posted record revenue (+11% YoY) but with margin compression (-70 bps) and a sharp cash flow decline (-93% YoY), while Tharimmune's divestiture improved its pro forma net loss by 28% but left it with a massive deferred tax liability. Insider activity is sparse, but the lack of insider tendering in several tender offers (Crestline, Fortress) signals low management conviction. Capital allocation trends show a shift towards buybacks (Gentherm's new $400M program) and strategic acquisitions for growth, while several companies face existential risks from non-compliance with listing standards. The most critical developments are the potential delisting of Nuvve and the insolvency of Manaksia Coated Metals, both with high materiality and immediate market implications.

42 high priority 42 total filings
· daily

US SEC Filings Daily Market Digest — July 23, 2026

Today's filings reveal a market characterized by strong top-line growth but significant margin compression and rising leverage across key sectors. Tech giants Alphabet and Tesla posted robust revenue growth of 24% and 26% YoY, respectively, yet Tesla's net income fell 5% due to a 57% operating income decline, highlighting cost pressures. Financials showed mixed results: KB Financial Group's H1 operating revenue surged 42% YoY, while regional banks like Independent Bank Corp and Northrim BanCorp reported improved net interest margins but sharp increases in non-performing loans. A notable capital allocation divergence is emerging—Alphabet's long-term debt surged 111% and goodwill rose 73%, suggesting aggressive M&A, while Comcast paused its buyback program amid a planned spin-off. Insider activity was sparse but included a concerning board member removal at Vale for leaking confidential information. The most actionable themes are the divergence in profitability within tech, the NIM expansion vs. credit quality trade-off in regional banking, and the growing use of debt-financed growth strategies.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 23, 2026

Tesla's Q2 2026 10-Q reveals a stark divergence between top-line growth and profitability. Revenue surged 25.5% YoY to $28.236B, driven by robust automotive sales (+26.7%) and a 50.4% jump in services revenue, signaling strong demand and expanding ecosystem monetization. However, operating income collapsed 56.9% YoY to $398M, and net income fell 4.9% to $1.114B, as operating expenses grew 47.3% and automotive regulatory credits plummeted 66.7%. This margin compression (operating margin fell from ~4.1% to ~1.4%) suggests aggressive pricing, investment in growth, and a normalization of high-margin credit sales. The mixed sentiment reflects a company gaining market share and diversifying revenue but at the cost of near-term profitability, a classic growth vs. margin trade-off that will test investor patience. The balance sheet remains solid with $15.2B cash, though liabilities grew faster than assets, warranting monitoring of leverage trends.

1 high priority 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 23, 2026

The S&P 500 Healthcare sector delivered a robust Q2 2026, with all reporting companies showing top-line growth, led by Edwards Lifesciences (+13.6% YoY) and Thermo Fisher (+10% YoY), while J&J posted a more moderate 6.6% increase. Margin performance was a key differentiator: Thermo Fisher and J&J expanded operating margins, whereas Edwards saw flat gross margins due to FX headwinds. The most critical development is Edwards' raised full-year guidance, signaling sustained momentum in structural heart devices. Insider activity was limited to routine equity awards at Vertex, providing no directional signal. Capital allocation is mixed, with Thermo Fisher pursuing a divestiture (microbiology business) while J&J maintains a strong balance sheet. The portfolio

3 high priority 3 medium 6 total filings
· daily

US Earnings Financial Results SEC Filings — July 23, 2026

This earnings season reveals a market bifurcated between top-line growth and bottom-line pressure. While 70% of reporting companies showed YoY revenue increases, a significant cohort experienced margin compression due to rising input costs (fuel, labor, interest) and elevated spending on M&A and AI infrastructure. The most pronounced profit squeeze is in the industrial and transportation sectors, where companies like American Airlines and Norfolk Southern saw fuel costs nearly double, crushing net income despite strong demand. Conversely, capital-light, asset-light business models like Moody's, Nasdaq, and Medpace demonstrated superior earnings leverage. A dominant theme is aggressive capital deployment: share repurchases surged across the board (T-Mobile $7.1B, Otis $807M, Medpace $297M), often funded by new debt issuance, signaling management confidence but also increasing financial leverage. Insider trading activity was notably absent from most filings, a potential neutral-to-slightly-bearish signal. The key takeaway for investors is to favor companies with pricing power and cost control (e.g., Comfort Systems, Hartford) over those exposed to volatile commodity costs (e.g., Airlines, Steel).

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 23, 2026

This executive compensation digest reveals a bifurcated landscape across the 13 filings. On one side, high-performance companies like Logitech and Transcat are rewarding executives with above-target bonuses and record PSU vesting, signaling strong operational momentum and management confidence. Conversely, several micro-cap and special situation filings, including VisionWave Holdings and CalciMedica, present complex governance proposals with heavy equity dilution, insider-driven transactions, and potential for significant shareholder value transfer. A notable theme is the prevalence of reverse stock split proposals (CalciMedica, VisionWave) and M&A-related compensation (First Seacoast, Forum Funds), which create both risks and opportunities for investors. The lack of insider selling or buying in most filings, combined with the high number of routine 'Say on Pay' votes, suggests a generally stable but cautious executive compensation environment, with the most actionable signals coming from the few companies with strong financial performance and clear forward-looking guidance.

13 high priority 13 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 23, 2026

The IPO pipeline for July 23, 2026, reveals a bifurcated market: one traditional operating company (Syntec Optics) is attempting to go public after resolving severe compliance issues, while two others (Innovative Eyewear and Lyntris) are burdened by weak financial health and governance red flags. AParadise Acquisition Corp. represents the SPAC sector, but its small size and forfeiture of founder shares signal muted sponsor confidence. No period-over-period revenue or margin trends are available across these pre-revenue or pre-IPO entities, but the absence of insider buying and the presence of material weaknesses in internal controls (Lyntris) and out-of-the-money warrants (Innovative Eyewear) suggest cautious investor sentiment. The most critical development is Lyntris's $284.7M debt load and unremediated control weaknesses, which could deter institutional participation. Overall, the pipeline lacks high-quality, growth-stage issuers, indicating a potential lull in new listings.

4 high priority 4 total filings
· daily

US SEC Trading Suspension Halt Orders — July 23, 2026

On July 22-23, 2026, five US-listed small-cap and micro-cap companies disclosed regulatory listing challenges, highlighting a concentrated round of Nasdaq compliance failures. The filings reveal two distinct themes: immediate trading suspensions/delistings (Nuvve Holding Corp.) and grace-period remediation efforts (Aprea Therapeutics, Fly-E Group, InspireMD, Shore Bancshares). A critical portfolio-level trend is the prevalence of non-compliance with the $1.00 minimum bid price rule (3 of 5 companies), alongside periodic reporting failures (2 of 5). No insider trading activity was reported by any of the companies, suggesting management may be limited in their ability to signal confidence amid regulatory uncertainty. Forward-looking data shows key catalyst dates through January 2027, creating a defined timeline for potential reversals or further downside. The most material development is Nuvve's imminent suspension and move to OTC Pink, representing a near-certain loss of exchange liquidity. The sector-wide pattern suggests increasing regulatory scrutiny on micro-cap compliance with Nasdaq's quantitative and procedural standards.

5 high priority 5 total filings
· daily

US Executive Officer Management Changes SEC — July 23, 2026

This digest covers 35 filings focused on executive and director changes, with a notable concentration of CFO transitions and board appointments. The most significant development is the CFO departure at GE HealthCare, a high-materiality event (8/10) accompanied by strong preliminary Q2 results (revenue +5.7% YoY, organic +3.5%) and reaffirmed guidance, creating a mixed signal. A wave of planned retirements and successions is evident, including the CEO of Popular, Inc., the CFO of Albertsons, and the founder-CEO of Mobileye, signaling a period of leadership renewal across sectors. Several companies are using compensation actions to retain key talent, such as Franklin Resources' $15M retention awards and Arq's restructured CEO agreement with aggressive stock price targets. The data reveals a bifurcated market: established firms like GE HealthCare and ADM are strengthening their benches with experienced operators, while smaller companies like Allurion and Cingulate face leadership vacuums or role eliminations. Insider activity is limited to compensation-driven grants, with no open-market buying or selling detected, suggesting management is focused on alignment rather than signaling conviction. The overall tone is neutral, with pockets of positive sentiment from strategic appointments and negative sentiment from sudden departures.

35 high priority 35 total filings
· daily

USA Insider Trading Pulse — July 23, 2026

The July 23, 2026 insider trading pulse reveals a bifurcated market: aggressive insider buying at beaten-down small-caps (Byrna Technologies, 51Talk, Energizer Holdings) contrasts with significant, high-value sales at large-cap leaders (Travelers, Credo Technology, Cytokinetics). The most notable cluster is the coordinated, large-scale option grant to six directors at Perma-Fix Environmental Services, signaling a strategic board-level refresh. Period-over-period comparisons from the enriched data show that insider sentiment is most positive in the environmental services and online education sectors, while the insurance and semiconductor supply-chain spaces show bearish conviction from top executives. A key pattern is the use of Rule 10b5-1 plans for sales at Travelers and Credo, suggesting pre-planned diversification rather than reactive fear, but the sheer dollar volume ($7.45M combined at Travelers) demands attention. The data also reveals a capital allocation theme of stock-for-tax withholding at MillerKnoll and Sun Communities, which is a neutral signal but indicates high equity compensation levels. Overall, the stream points to a 'risk-on' rotation by corporate insiders into undervalued growth stories, while insiders at high-flying names are taking profits.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 23, 2026

The July 23, 2026 filings reveal a bifurcated US M&A landscape: SPAC activity remains robust with two new IPOs (B&R Technology Merger Corp. raising $325M and Southern Cross Acquisition I Corp. raising $100M) and three SPACs extending deadlines (Cayson, Four Leaf, and Bleichroeder's Pasqal deal progressing), signaling sustained appetite for blank-check vehicles despite market volatility. However, the most actionable intelligence comes from operating companies: Gentherm posted record revenue ($416.2M, +11% YoY) but experienced margin compression (-70 bps) and a dramatic cash flow decline (from $31.7M to $2.3M), while raising guidance and announcing a $400M buyback—a mixed signal. Tharimmune's divestiture of Gravitas Life Sciences for a $3.5M promissory note improves its loss profile (pro forma net loss improving from -$35.9M to -$25.8M for FY2025) but leaves it with a $113.7M deferred tax liability and ongoing digital asset losses. XMax's indirect investment in Figure AI via a fund structure (48% interest for $8M) represents a novel SPV approach to accessing high-growth private AI. Portfolio-level trends show SPACs dominating volume (6 of 10 filings) but operating companies providing the most material financial insights, with period-over-period comparisons highlighting revenue growth offset by margin and cash flow deterioration.

10 high priority 10 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 23, 2026

Overnight filings reveal a market bifurcated between strong operational performance and rising strategic uncertainty. Columbia Financial Inc. saw an extraordinary wave of insider buying, with 12 executives and directors collectively purchasing over $3.3 million of stock at $10.00 per share, signaling profound conviction in a deeply undervalued asset. Conversely, a high-stakes governance battle is unfolding at Hilltop Holdings, where the largest shareholder (26.7% stake) is voting against all directors and executive compensation, creating significant headline risk. On the earnings front, Alphabet and Thermo Fisher delivered standout results, with revenue surging 24% and 10% respectively, though Alphabet's massive net income jump was driven by non-operating items. Tesla's Q2 showed a worrying divergence: revenue grew 25.5% YoY, but operating income collapsed 56.9% due to soaring expenses, and regulatory credit revenue plunged 67%. Comcast's mixed report highlighted a strategic pivot, with a share repurchase pause and record wireless additions, but continued broadband losses. A key portfolio-level trend is the divergence in capital allocation: while Allegion aggressively bought back shares (+101% YoY), Comcast paused its program, signaling different stages of corporate lifecycle and strategic transformation.

35 high priority 15 medium 50 total filings
· daily

New Federal Contractors — July 22, 2026

This digest covers two defense-related contracts totaling $278.5 million, with a 100% defense/civilian split (both are defense-related). The dominant theme is a mix of legacy NASA mission assurance work and a current FDA public health communications campaign, indicating no single sector concentration. The highest-conviction signal is the $95.8 million TRUE NORTH COMMUNICATIONS INC award from the FDA, which provides multi-year revenue visibility through December 2026 but carries execution risk tied to civilian agency appropriations. A key watch item is the lack of recent contract wins for ARES TECHNICAL SERVICES CORPORATION, whose $182.7 million NASA contract ended in 2019, limiting forward revenue visibility.

2 total filings